Drug intelligence / Profile preview

OCNR-100

Development stage: Preclinical
Lead developer: Onconic Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

OCNR-100 is a preclinical-stage small molecule dual-target anticancer drug being developed by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical. It is designed to target the DNA damage response (DDR) pathway to induce synthetic lethality, specifically aiming to treat solid tumors. OCNR-100 is being investigated as a potential therapy for patients with solid tumors, including those who have developed resistance to conventional PARP inhibitors, or to be used in synergistic combination with other PARP inhibitors.

Beyond the preview

Go deeper on OCNR-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCNR-100.

Explore the full profile